Patent · US Expired

2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding

US5534408A · kind A · utility

60Cited by

1References

54Claims

0Family size

Assignee

University of Massachusetts Medical Center · US

Inventors

Michael R. Green · Geneva, US
Maria L. Zapp · Boylston, US
Seth Stern · Palo Alto, US

Key dates

Filing date	Sep 24, 1993
Grant date	Jul 9, 1996
Priority date	—
Expiry date	Sep 24, 2013

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a method for the inhibition of binding of a ligand to an RNA, the inhibition being mediated by a small organic molecule which binds to the RNA, thereby inhibiting ligand binding. A preferred class of small organic molecules are the 2-deoxystreptamine (2-DOS) aminoglycosides. Disclosed herein are members of the 2-DOS class that are useful for the inhibition of binding of Rev to an RNA containing an RRE. In an HIV infected cell, a consequence of the inhibition of the ability of Rev to bind to the RRE in HIV encoded transcripts is inhibition of HIV replication.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.